Zacks Research Downgrades Elekta (OTCMKTS:EKTAY) to Strong Sell

Elekta (OTCMKTS:EKTAY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Elekta Stock Down 2.2%

EKTAY stock opened at $5.63 on Tuesday. The company has a current ratio of 0.95, a quick ratio of 0.73 and a debt-to-equity ratio of 0.56. The company’s 50 day moving average is $5.99 and its 200 day moving average is $6.02. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -35.19 and a beta of 1.00. Elekta has a 1-year low of $4.35 and a 1-year high of $6.93.

Elekta (OTCMKTS:EKTAY) last posted its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $521.00 million for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 10.67%. Sell-side analysts predict that Elekta will post 0.43 EPS for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.